Cystinosis patients face lifelong organ damage from cystine crystal accumulation, requiring constant medication and ultimately kidney transplants. This rare genetic disorder stems from defects in the CTNS gene, which encodes cystinosin, the protein responsible for transporting cystine out of cellular compartments called lysosomes. The therapeutic challenge has long been delivering functional copies of this gene to affected tissues throughout the body. Researchers successfully used hematopoietic stem cell gene therapy to address cystinosis by extracting patients' bone marrow stem cells, inserting functional CTNS genes using viral vectors, then reinfusing these corrected cells. The modified stem cells differentiated into various blood cell types carrying the therapeutic gene, potentially reaching multiple organ systems affected by the disease. Early results demonstrated reduced cystine accumulation in white blood cells and improved cellular function markers. This represents a significant advance over current cystine-depleting drugs like cysteamine, which require frequent dosing and cause gastrointestinal side effects while failing to prevent all organ damage. The gene therapy approach could theoretically provide sustained therapeutic benefit by creating a renewable source of cells capable of cystine clearance. However, this remains early-stage research with limited patient numbers and short follow-up periods. The durability of genetic correction, long-term safety profile, and whether the therapy can prevent or reverse existing organ damage require extensive validation. While promising for this ultra-rare disease affecting roughly 2,000 people worldwide, the approach must demonstrate sustained efficacy across diverse patient populations before becoming standard care.